In Brief
T cell lymphomas (TCL) overexpress the c-Myc protein without MYC rearrangements or amplification. Gu et al. show that CAMKIIg stabilizes c-Myc by phosphorylating it at Ser62, that the CAMKIIg level positively correlates with the c-Myc level in patient TCL, and that inhibition of CAMKIIg reduces TCL burden in mice.
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INTRODUCTION
The transcription factor c-Myc regulates many genes involved in essential biological processes, including cell growth, proliferation, and apoptosis (Cole, 1986; Dang, 2012; Prendergast, 1999) . In malignant diseases it promotes oncogenesis by activating and repressing target genes controlling cell growth and proliferation (Nilsson and Cleveland, 2003) . C-Myc is dysregulated in many human cancers, especially in a large proportion of aggressive B cell lymphomas (BCL). The significance of c-Myc dysregulation has also been recognized in T cell lymphomas (TCL): Studies in the Em-tTA/tetO-Myc conditional mouse model have demonstrated that the development of aggressive TCL is a consequence of c-Myc overexpression
Significance
Rearrangements of MYC are rarely observed in certain cancers, including T cell lymphomas (TCL), in which the c-Myc protein is overexpressed. Our cumulative findings provide an explanation for this phenomenon, CAMKIIg appearing to be a kinase essential for maintaining the c-Myc protein level. Thus the CAMKIIg:c-Myc axis appears to fundamentally support the development of TCL. The mechanism for TCL development is not fully understood, and TCL in general has poor treatment outcomes. Because c-Myc is an ''undruggable'' target, it is essential to identify important c-Myc regulators that can be targeted. Here we identify CAMKIIg as such a regulator and show that a CAMKIIg-specific inhibitor potently eliminates TCL burden with minimal toxicity. Therefore, these studies define a potential therapeutic approach for treating TCL. (Choi et al., 2014; Koh et al., 2015) . Mechanisms underlying aberrant activity of the c-Myc oncoprotein have been defined in Burkitt and some other aggressive BCL, where molecular hallmarks include chromosomal rearrangements of MYC (Rossi et al., 2012) . In contrast, TCL rarely exhibit such MYC rearrangements (Chisholm et al., 2015) . To date, the mechanisms of c-Myc overexpression in TCL are still unknown. Ca 2+ /calmodulin-dependent protein kinase II (CAMKII), a multi-functional serine/threonine kinase best known for its regulatory functions in learning and memory (Bui et al., 2000) , can be chronically activated under pathological conditions (Hook and Means, 2001; Nowycky and Thomas, 2002; Orrenius et al., 2003) . For example, in some tumors the aberrant expression of CAMKII and its tumor-promoting functions have been investigated (Colomer and Means, 2007; Meng et al., 2013) . According to both our work and that of others, the major isoform of CAMKII in hematopoietic cells, namely CAMKIIg, plays a role in leukemia (Gu et al., 2016; Si and Collins, 2008) . While both CAMKIIg action and Ca
2+
-related signaling pathways are important components of normal signal transduction in T lymphocytes (Lin et al., 2005) , the oncogenic functions of CAMKIIg in TCL remain uncharacterized.
With current therapy, survival of patients having TCL with high c-Myc activity is dismal. One contributor to the poor outcome is the current lack of therapeutics against c-Myc; it has been notoriously difficult to target c-Myc with small-molecule inhibitors (Toyoshima et al., 2012) . Interestingly, CAMKII has been recently implicated in the survival of c-Myc-overexpressing cells (Toyoshima et al., 2012) : CAMK2G was determined to be one of 102 potential genes involved in a synthetic lethal interaction with c-Myc (concomitant mutations lead to cell death). These results suggest that CAMKIIg may be involved in c-Myc-associated malignancies; however, there is no further study regarding their interactions and functions. Our previous investigations of CAMKIIg suggest that it is a specific and critical target through which berbamine (BBM) conveys its anti-tumor activity (Gu et al., 2012) . Such findings highlight a potential therapeutic strategy whereby c-Myc-associated malignancies are targeted by inhibiting CAMKIIg. Toward this end, we are delineating the role CAMKIIg plays in c-Myc-associated tumors.
RESULTS
Camk2g Deletion Suppresses T Cell Lymphomagenesis In Vivo
To examine the role of CAMKIIg during T cell lymphomagenesis in vivo, we used a chemical-induced TCL-like mouse model. Through a single injection of N-methyl-N-nitrosourea (MNU) as described previously ( Figure S1A ) (Dumenco et al., 1993; Joshi and Frei, 1970; Slee and Lu, 2013) , we induced a lymphomagenesis in 4-to 5-week-old Camk2g À/À mice (Backs et al., 2010) and wild-type mice. Disease onset was verified by symptoms such as hunched posture and labored breathing. At approximately 6 months after MNU injection, wild-type mice exhibited the expected significantly enlarged thymuses, spleens, and lymph nodes ( Figures 1A and 1B) . Histological analysis of wild-type mice showed evidence of malignant lymphoma. This included effacement of the thymic corticomedullary architecture by diffuse sheets of lymphoblasts with large euchromatic nuclei; moderate to high numbers of mitotic figures; and the presence of clusters or sheets of lymphoblasts in lymph nodes and spleens (Figures 1C and 1D) . The neoplastic cells exhibited positive staining for CD3 antigen, indicating that the neoplasms originated from the T cell lineage ( Figures 1C and 1D) . Nevertheless, during MNU-induced TCL development, the white cell differential counts in peripheral blood did not differ significantly from those in normal (without MNU) mice ( Figure S1B ). In contrast, Camk2g À/À mice were resistant to MNU-induced lymphoma. By 38 weeks, all of the wild-type mice had died from the disease while 90% of the Camk2g À/À mice still survived ( Figure 1E ). These studies demonstrate that Camk2g deletion suppresses the development of MNU-induced TCL in mice; thus, CAMKIIg appears to be essential for in vivo T cell lymphomagenesis. (Table S1 ). We then performed IPA (Ingenuity Pathway Analysis) to predict for such changes potentially associated with upstream regulators (Table S2) . Importantly, c-Myc, which is reported as a key player in BCL and many other malignancies, ranks #2 in the list. The rank #1 position of our upstream analysis was tripartite motif-containing 24 (TRIM24). Prompted by these results, we checked the expression of TRIM24 and c-Myc in thymuses of both wild-type and Camk2g À/À mice, under either malignant or normal conditions. Notably, c-Myc displayed a highly positive correlation with CAMKIIg expression status, compared with that of TRIM24 ( Figure S2B ). Consistently, we found a distinct set of known c-Myc target genes upregulated in wild-type/+MNU mouse thymuses but not in the thymuses of Camk2g À/À mice ( Figure 2A ). According to gene set enrichment analysis (GSEA) in wild-type/+MNU mouse thymuses, transcription targets of c-Myc were enriched compared with those in Camk2g
CAMKIIg Maintains the c-Myc Protein Levels during T Cell Lymphomagenesis
/+MNU mice ( Figure S2C ). Although there were no significant differences in the Myc mRNA levels ( Figure S2D ), a strong increase in the c-Myc protein levels was detected in wild-type but not Camk2g À/À mice ( Figure 2B ).
To further address the roles of CAMKIIg in c-Myc-related T cell tumorigenesis, we then performed bone marrow transplantation (BMT) experiments using hematopoietic progenitors from wildtype or Camk2g À/À mice ( Figure S2E ). We transplanted isogenic C57BL/6 mice with wild-type or Camk2g À/À hematopoietic progenitors infected with retroviruses driving the expression of an oncogenic constitutively active form of Notch1 (Notch1-DE) (Herranz et al., 2014; Schroeter et al., 1998) . The tumorigenetic kinetics displayed a much faster disease onset in the wild-type background than in the Camk2g À/À background: We observed
(1) significantly faster increase in the frequency of CD4 + CD8 + double-positive cells ( Figure 2C ) and tumor burden in the peripheral blood ( Figures 2D and 2E) ; (2) more severe infiltration of lymphoblasts in the thymuses; and (3) the presence of clusters or sheets of lymphoblasts in spleens and livers ( Figure S2F ). Moreover, the wild-type mice succumbed to the disease much faster than Camk2g À/À mice ( Figure 2F ). Consistently, in Notch1-DE-expressing mouse bone marrow cells (BMCs) from the wild-type background, the c-Myc protein levels were much higher than those observed in the Camk2g À/À model ( Figure 2G ).
Notably, the Myc mRNA levels observed in both of these backgrounds were not significantly different ( Figure S2G ). Altogether, these results suggest that high protein levels of c-Myc depend on CAMKIIg in TCL.
CAMKIIg:c-Myc Axis Enhances T Cell Lymphoma Cell Proliferation
We next examined whether CAMKIIg:c-Myc axis is required for TCL's cellular proliferation in vitro. A set of TCL cell lines comprising H9, JB6, Jurkat, and SU-DHL-1 was treated with a widely used specific CAMKII inhibitor, KN93 (Rich and Schulman, 1998; Sumi et al., 1991) . For all these cell lines, KN93 suppressed their growth ( Figure S3A ). This suppression was not observed for KN93's related, inactive analog KN92. Using the H9 cell line as a representative example, genetic ablation of CAMK2G (H9 CAMK2GÀ/À ), via clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) technology ( Figure 3A ), also dramatically suppressed cellular proliferation ( Figure 3B ) (Ran et al., 2013; Xue et al., 2014) . Moreover, in H9 CAMK2GÀ/À cells, flow-cytometric analysis showed a significant increase in the percentage of G 2 /M-phase cells and a significant decrease in the percentage of S-phase cells ( Figure 3C ). Deletion of CAMK2G in TCL cells therefore appears to induce G 2 /M arrest, a feature that is consistent with inhibition of cell proliferation. Annexin V (AV) and propidium iodide (PI) double staining showed that, upon deletion of CAMK2G, the percentage of total apoptotic cells in H9 CAMK2GÀ/À cells was 9.63%, compared with 3.5% in H9 cells ( Figure 3D ). Furthermore, both knocking out CAMK2G by CRISPR/Cas technology and inhibiting CAMKIIg activity by KN93 in H9 cells decreased the protein levels of c-Myc, but not other lymphoma-associated signaling molecules ( Figure S3B ) nor the MYC mRNA levels ( Figure S3C ). We then asked whether c-Myc overexpression can reverse the repercussions of deleting CAMK2G, i.e., the impaired cellular proliferation. As shown in Figure 3E , overexpression of c-Myc Data represent the mean ± SD for 8 mice. *p < 0.05, **p < 0.01. See also Figure S1 .
in H9 CAMK2GÀ/À cells indeed rescued their ability to proliferate ( Figure 3E ). As with deleting CAMK2G, knocking down c-Myc in H9 cells also dramatically suppressed proliferation; however, in this scenario, CAMKIIg overexpression only slightly improved the impaired ability to proliferate ( Figure S3D ). In addition, we investigated whether CAMKIIg is required for c-Myc's transcriptional activity. Knockout of the endogenous CAMK2G reduced c-Myc transcriptional activity ( Figure 3F ), whereas overexpression of CAMKIIg significantly increased c-Myc transcriptional activity ( Figure S3E ). Considering the results altogether, CAMKIIg positively regulates the proliferation of TCL cells by sustaining c-Myc levels and activities.
CAMKIIg Positively Regulates the c-Myc Protein Stability Increased c-Myc protein abundance may be caused by either increased c-Myc production or decreased decay. Both modes have been reported as a mechanism of c-Myc overexpression in various malignancies (Lim and Elenitoba-Johnson, 2004; Thomas and Tansey, 2011 prolonged by CAMKIIg overexpression, suggesting that CAMKIIg positively regulates the half-life of the c-Myc protein ( Figures 4C-4E ). In contrast, the half-life of another unstable protein expressed ectopically, HT-tagged p53 (HT-p53), was not altered by the status of CAMKIIg, suggesting the specific regulation of c-Myc stability by CAMKIIg ( Figure S4D ). Thus, CAMKIIg is able to stabilize the c-Myc protein in TCL.
CAMKIIg Stabilizes c-Myc by Enhancing c-Myc Phosphorylation at Serine 62
The tight control of c-Myc activity is defective at multiple levels in cancers in which the protein is constitutively activated and stabilized (Wang et al., 2011a) . c-Myc protein stability can be regulated by two phosphorylation sites with opposing functions: serine 62 phosphorylation (pS62) stabilizes c-Myc whereas threonine 58 phosphorylation (pT58) promotes c-Myc degradation (Pulverer et al., 1994; Sears et al., 1999) . We therefore hypothesized that the dependence of c-Myc turnover on CAMKIIg most likely involves CAMKIIg kinase activity. We transiently transfected H9 CAMK2GÀ/À cells separately with various hemagglutinin (HA)-tagged CAMKIIg mutant expression plasmids. As anticipated, a positive correlation between CAMKIIg activity and c-Myc/pS62-c-Myc levels was observed. Compared with cells that were CAMK2G À/À or expressing K43M mutant (kinase dead), those expressing wild-type or T287D mutant (constitutively active) CAMKIIg had elevated levels of c-Myc/pS62-c-Myc ( Figure 5A ). The ubiquitin-proteasome pathway is known to proteolytically degrade c-Myc (Lim and Elenitoba-Johnson, 2004; Thomas and Tansey, 2011) . According to our results, the proteasome inhibitor MG132 abolished the differential c-Myc protein levels we observed in transfected cells ( Figure 5A ). We also investigated phosphorylation after CAMKIIg inhibition by KN93. To do so, we used two antibodies specific to phosphorylated S62 and two antibodies specific to phosphorylated T58; the specificity of these antibodies was validated using S62A or T58A c-Myc mutants, respectively ( Figure S5A ). Using H9 cells as a representative example, KN93 decreased p-CAMKIIg, c-Myc, and pS62-c-Myc, but not pT58-c-Myc levels, in a dose-and time-dependent manner (Figures S5B and S5C) . Compared with our results in the above CAMKIIg inhibition model, we observed similar phosphorylation status at S62 and T58 in H9 cells with or without endogenous CAMKIIg ( Figure 5B ). Since CAMKIIg positively regulated c-Myc half-life in our four TCL cell lines ( Figure 4B ), we interrogated whether this phenomenon involved changes in phosphorylation at T58 or S62. Phosphor-specific antibodies were used to examine the phosphorylation status of c-Myc at T58 or S62. Compared with levels in control cells expressing CAMKIIg, CAMKIIg knockdown cells exhibited remarkably lower pS62-c-Myc and total c-Myc; in contrast, cells in which CAMKIIg was overexpressed exhibited higher levels of pS62-c-Myc and total c-Myc protein levels, but not pT58-c-Myc ( Figure 5C ). Strikingly, in all cell lines in which CAMKIIg was overexpressed the pS62/pT58 c-Myc ratios were remarkably higher, which is consistent with a prolonged c-Myc half-life. Conversely, CAMKIIg knockdown significantly decreased pS62/pT58 ratios of c-Myc, which is consistent with decreased c-Myc stability ( Figure 5D ). These results suggest CAMKIIg stabilizes the c-Myc protein by enhancing S62 phosphorylation of c-Myc. S62 phosphorylation must precede phosphorylation of T58, which in turn facilitates dephosphorylation at S62 (Pulverer et al., 1994; Sears et al., 1999) . As such, S62 mutations may alter this process and, as a result, the turnover of c-Myc. To further examine the impact of CAMKIIg-mediated S62 phosphorylation on c-Myc turnover, we used S62D and S62A c-Myc mutants. The half-life of the wild-type c-Myc was prolonged by CAMKIIg overexpression and significantly shortened by CAMK2G deletion ( Figure 4E ). According to our results and consistent with previous reports, HT-c-Myc S62D exhibited prolonged half-lives (>100 min) in cells. Importantly, neither knockout nor overexpression of CAMKIIg influenced HT-c-Myc S62D turnover ( Figure 5E ). The half-life of c-Myc S62A in mammalian cells is reported to be either shorter (Sears et al., 2000) or somewhat longer (Wang et al., 2011b) than the wild-type c-Myc. In our experiments, we observed rapid turnover ($30 min) of HT-c-Myc S62A and, as expected, CAMKIIg knockout or overexpression did not influence its turnover ( Figure S5D ). These results thus indicate that CAMKIIg may stabilize c-Myc by enhancing c-Myc phosphorylation at S62.
CAMKIIg Directly Phosphorylates c-Myc at S62 in T Cell Lymphoma
To obtain biochemical evidence for a direct interaction between CAMKIIg and c-Myc, we carried out a co-immunoprecipitation experiment using H9 cell lysates. C-Myc was co-immunoprecipitated by the CAMKIIg antibody but not the control immunoglobulin G ( Figure 6A ). Like c-Myc, TRIM24 was also high in our upstream analysis list (Table S2 ), yet no specific interaction was observed between CAMKIIg and TRIM24 ( Figure S6A ). An in vitro kinase assay using recombinant CAMKIIg and c-Myc proteins showed that CAMKIIg directly phosphorylated c-Myc at S62. Accordingly, a CAMKII-specific inhibitor, CaMKIINtide, diminished pS62-c-Myc ( Figure 6B ). Moreover, the S62D mutation conferred resistance to KN93-induced downregulation of ectopically expressed c-Myc ( Figure 6C ). Altogether, these results indicate a role for CAMKIIg in stabilizing the c-Myc protein by directly phosphorylating them at S62. We next examined the relationship between proliferation of TCL and the ability of CAMKIIg to phosphorylate c-Myc at S62. To this end, we combined in H9 cell knockout/overexpression of CAMKIIg with S62A or S62D mutant c-Myc. In brief, we first established two pairs of H9 stable cell lines containing different CAMKIIg levels: H9 and H9 CAMK2GÀ/À , and H9 pCDHÀCAMKIIg and H9 Figure 6F) ; similarly, CAMKIIg knockout/overexpression in c-Myc S62A mutant also did not significantly influence the abilities of proliferation and colony formation ( Figures S6B and S6C ). Therefore, the functions of CAMKIIg:c-Myc axis in promoting TCL cell growth are dependent on S62 phosphorylation by CAMKIIg.
Pharmacological Inhibition of CAMKIIg Destabilizes the c-Myc Protein, Efficiently Suppresses T Cell Lymphomagenesis, and Reduces Tumor Burden C-Myc is broadly implicated in human cancers yet is considered ''undruggable'' (Toyoshima et al., 2012). Our results suggest that
CAMKIIg inhibitors have therapeutic potential for c-Myc-overexpressing cancers. However, KN93, a widely used specific inhibitor for CAMKII, is not a good candidate for clinical use (Pellicena and Schulman, 2014). We therefore examined BBM, which we identified previously as a specific pharmacological inhibitor of CAMKIIg (Gu et al., 2012) . We first treated H9 cells for 24 hr with various concentrations of BBM and used the MTS assay to measure cell proliferation. BBM suppressed the growth of H9 cells (IC 50 = 22.7 mM) ( Figure S7A) ; it also decreased, in a time-dependent manner, levels of p-CAMKIIg and CAMKIIg protein ( Figure S7B ). To assess the inhibitory effects of BBM on TCL development in vivo, we treated MNU-injected wild-type or Camk2g À/À mice with or without BBM. Based on previously observed time courses for lymphoma to develop (Joshi and Frei, 1970) , we administered BBM during two 14-day treatment periods separated by 14 days (Figure S7C) . Only vehicle-treated wild-type, but not Camk2g
mice, developed significantly enlarged thymuses, spleens, and lymph nodes. Importantly, in these wild-type mice, BBM treatment dramatically reduced (compared with the vehicle control group) the lymphoma size and cellularity of the infiltrated thymuses, spleens, and lymph nodes ( Figures 7A, 7B , and S7D, S7E). Moreover, BBM-treated wild-type mice displayed strong resistance to MNU-induced lymphoma regarding the disease symptoms, histological severity, and significant prolonged survival ( Figure 7C ). In contrast, there were no obvious differences between the vehicle Data represent the mean ± SD of three independent experiments. n.s., not significant; *p < 0.05, **p < 0.01. Scale bars, 250 mm. See also Figure S6 .
control group and BBM-treatment group in Camk2g À/À mice (Figure S7F ). As expected, BBM treatment significantly decreased pS62-c-Myc level and c-Myc protein levels ( Figure 7D ). We also examined the effect of CAMKIIg inhibition in a pre-established tumor model. Briefly, 5 3 10 6 H9 cells were inoculated subcutaneously in the flank of NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice. After the xenografted tumors reached a volume of $100 mm 3 (day 16 after cell injection), they were randomized to two groups to receive either vehicle or BBM treatment via oral gavage twice a day for 23 days ( Figure S8A) . A dramatic reduction in tumor volume was observed with the administration of BBM compared with that treated with vehicle ( Figures 7E and  S8B) . On day 40, all mice were euthanized and tumor tissues processed for H&E staining, and immunostained for Ki-67 and TUNEL. There was no significant difference in body weight between mice in these two treatment groups, suggesting low toxicity of BBM ( Figure S8C ). Compared with the vehicle control group, the BBM-treatment group exhibited a significant decrease in c-Myc or pS62-c-Myc levels in the xenografted tumors ( Figure 7F ). In BBM-treated mice, a greater number of dead cells and decreased number of proliferating cells were observed ( Figures S8D and S8E ). Based on these results, targeting CAMKIIg in TCL may be a rational therapeutic strategy.
C-Myc and CAMKIIg Overexpress in Human T Cell Lymphoma with a Positive Correlation
We next investigate the potential correlation between CAMKIIg and c-Myc/pS62-c-Myc in human TCL. We measured their protein levels in specimens from 32 TCL patients representing three subtypes of human TCL: angioimmunoblastic TCL (AITL, n = 10), peripheral TCL -not otherwise specified (PTCL-NOS, n = 11), and extranodal natural killer/TCL (NK/TCL, n = 11); and benign lymph node specimens (n = 9). As expected, compared with the benign lymph node tissues, CAMKIIg was highly expressed in the three TCL subtypes (Figures 8A and 8B ; Table S3 ). In accordance with a previous report (Chisholm et al., 2015) , c-Myc and pS62-c-Myc expression levels were also significantly higher (compared with benign lymph nodes) in all three lymphoma subtypes (Figures 8A and 8B ; Tables S4 and S5 ). More importantly, there was a positive correlation between CAMKIIg and c-Myc expression (r 2 = 0.807, p < 0.01), as well as pS62-c-Myc (r 2 = 0.826, p < 0.01; Figure 8C ). The results are consistent with a role for CAMKIIg in c-Myc overexpression in human TCL.
DISCUSSION
MYC encodes a transcription factor that is overexpressed in $70% of human cancers and drives unrestrained cell growth Tables S3-S5. and proliferation. Approximately 20% of such c-Myc cancers, such as Burkitt lymphoma and breast cancer (Nesbit et al., 1999) , exhibit MYC translocations or amplifications. Such genomic alterations may help explain the high expression of the c-Myc protein in these tumors. In other cancers, however, overexpression of the c-Myc protein likely depends on alternative mechanisms. Indeed, a recent report on expression profiling of the c-Myc protein and MYC rearrangements in 1,214 lymphomas indicates that the c-Myc protein is overexpressed in about 94% of TCL; importantly, none possess MYC rearrangements (Chisholm et al., 2015) . Our current study provides such an alternative mechanism. That is, in lymphomas without MYC rearrangements, the CAMKIIg:c-Myc axis may contribute to c-Myc-associated tumorigenesis.
In our study, we used two mouse models to establish a molecular link between CAMKIIg and T cell lymphomagenesis: (1) the MNU-induced murine TCL model, in which a nitroso compound MNU induces thymic lymphomas in mice (Dumenco et al., 1993; Joshi and Frei, 1970; Slee and Lu, 2013) ; and (2) the Notch1-DEdriven murine T cell leukemia/lymphoma model, which is well characterized and relatively fast (Herranz et al., 2014; Schroeter et al., 1998) . In both models, CAMKIIg upregulates c-Myc at the protein level instead of enhancing gene transcription or mRNA stability (Cole and Cowling, 2008; Dai and Lu, 2008; van Riggelen et al., 2010) . Previous studies have demonstrated that alteration of S62 and T58 phosphorylation levels with consequent increased c-Myc stability in tumors could explain the observed c-Myc overexpression in the absence of gene amplification (Farrell and Sears, 2014) . In many cancers, the c-Myc protein exhibits high S62 phosphorylation and low T58 phosphorylation, and is aberrantly stabilized (Malempati et al., 2006; Zhang et al., 2012) . This could be due to a deregulated proteolysis through the ubiquitin-proteasome pathway (Lim and ElenitobaJohnson, 2004; Thomas and Tansey, 2011) . Consistently, our study shows that CAMKIIg stabilizes the c-Myc protein by directly phosphorylating c-Myc at S62. We conclude that CAMKIIg is a direct upstream regulator of the c-Myc protein levels in TCL. We go on to show that the functions of CAMKIIg:c-Myc axis are dependent on phosphorylating c-Myc at S62 by CAMKIIg specifically, suggesting that CAMKIIg through c-Myc is responsible for maintaining malignant growth of TCL cells.
Although there has been some progress in TCL research (Crescenzo and Inghirami, 2015) , TCL is known for its poorly understood mechanisms and unsatisfying treatment outcomes (Barrett et al., 2014; Lim and Levy, 2014; Piccaluga et al., 2007) . Therefore, it is urgent to identify potential therapeutic targets for these diseases. C-Myc inactivation in established tumors is sufficient to induce tumor regression through processes such as proliferative arrest, cellular senescence, apoptosis, and the shutdown of angiogenesis (Giuriato et al., 2006; Wu et al., 2007) . While c-Myc is considered a poor therapeutic target, our findings indicate that CAMKIIg could be an alternative target for TCL treatment. Our previous study has shown that CAMKIIg is a target of the natural compound BBM, which is isolated from the traditional Chinese herbal medicine Berberis amurensis (Dong et al., 2004; Xie et al., 2009 ). In our current studies, BBM has displayed potent effects to suppress TCL growth in mice and human TCL cells. The scaffold thus holds potential as a pharmacological agent for treating TCL. In summary, our study indicates that CAMKIIg is a plausible molecular target for the treatment of TCL; and that BBM or its derivatives (Nam et al., 2012) may have clinical usefulness in TCL treatment. Furthermore, our results raise the intriguing possibility of targeting CAMKIIg to treat other c-Myc-associated malignancies with the same underlying mechanism.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: MNU-Induced Murine Lymphoma Model N-methyl-N-nitrosourea (MNU) is a well-known carcinogen that induces TCL in mice. MNU causes neoplasia by alkylation and/or methylation-mediated mutagenesis of nucleic acids, proteins, and lipids. Two groups of C57BL/6J mice-wild-type and Camk2g À/À at 4-5 weeks of age-were given a single intraperitoneal injection of MNU (75 mg/kg) on Day 1 followed by an observation period; and the mice were observed weekly for tumor formation. MNU (Sigma) was dissolved in cold PBS immediately before treatment and injected within 1 hr.
BBM Treatment for MNU-Induced Murine Lymphoma BBM was dissolved in pure sterile water. Mice were randomly assigned to experimental groups as illustrated in Figure S7C . Administration of BBM was divided into 3 stages: (1) At day 40 after MNU injection, 50, 100, or 150 mg/kg BBM, or vehicle only, was orally administered to mice 2 times a day for 14 days; (2) administration was interrupted for 14 days; (3) at day 68 after MNU injection, 50, 100, or 150 mg/kg BBM, or vehicle only, was again administered to mice 2 times a day for 14 days. Sizes of the thymuses, spleens, and lymph nodes were calculated using the equation Volume (mm 3 ) = ½ ab 2 , where a = length and b = width of each organ.
Murine Xenograft Model 5 3 10 6 H9 cells were inoculated subcutaneously in the right flank of female NSG mice. After the xenografted tumors reached a volume of $100 mm 3 , they were randomized to two groups to receive either vehicle or BBM treatment via oral gavage twice a day. Tumors were measured every other day with Vernier calipers and mice were euthanized and sacrificed when tumor volume exceeded 3000 mm 3 in any dimension.
Murine Bone Marrow Transduction/Transplantation Model
The retroviral vector MSCV-IRES-eGFP carrying the activated form of the Notch1 (Notch1-DE) cDNA was used to make high-titer, helper-free, replication-defective ecotropic virus stock by transient transfection of 293T cells. Six-to eight-week-old female wild-type or Camk2g À/À C57BL/6 mice were used as donor mice for tumorigenesis experiments. Bone marrow from 5-fluorouracil (5-FU) -treated (150 mg/kg) donor mice was transduced two times with Notch1-DE retrovirus by cosedimentation in the presence of interleukin-3 (IL-3), IL-6 and stem cell factor. Syngeneic wild-type recipient mice were prepared by 1300 cGy g-irradiation and a dose of 0.5 3 10 6 transfected cells transplanted via tail vein injection. After transplantation, recipient mice were evaluated daily for signs of morbidity, weight loss and failure to thrive.
Patient Specimens
The formalin-fixed paraffin-embedded sections of TCL patients were obtained from the Pathology departments (Second Affiliated Hospital of Zhejiang University; and Tianjin Medical University Cancer Institute and Hospital). Image-Pro Plus 6.0 software was used for semi-quantitative analysis by randomly selecting five high-power fields from each slide and was used to calculate the sum integrated optical density (IOD) of the mean density, and the IOD of the positive staining in each field, as well as the mean value of these parameters.
Immunoprecipitation Assay
Cell extracts composed of 1 3 10 7 cells were prepared by solubilization in 1 ml IP lysis buffer (Thermo) in the presence of protease inhibitor cocktail (Thermo) for 10 min at 4 C. After a brief sonication step, the lysates were cleared by centrifugation at 15,000 3 g for 10 min at 4 C; and the cell extract was immunoprecipitated with 2 mg of antibodies against CAMKIIg or IgG control. The mixture was incubated with 60 ml of protein G plus protein A agarose for 16 hr at 4 C by continuous inversion. Immuno-complexes were pelleted and washed 5 times with IP lysis buffer. The precipitated immuno-complexes were then boiled in lane marker sample buffer (Thermo) and subjected to western blot analysis using an anti-c-Myc antibody.
Mouse Tumor Histopathology and IHC Staining Tumor specimens were prepared and analyzed by board-certified pathologists. Tumors were fixed in 4% PBS-buffered formalin; dehydrated and embedded in paraffin; and sectioned and processed for hematoxylin and eosin (H&E) staining. The sections were deparaffinized; heated for antigen retrieval; and incubated with the primary antibody CD3 (Abcam) or Ki-67. The secondary antibody was biotinylated with polyclonal anti-rabbit immunoglobulin (Dako) in combination with streptavidin/horseradish peroxidase (Dako). The sections were lightly counterstained using hematoxylin. Microscopy was performed by using an EVOS Ò FL Auto Imaging System (Life technologies) for photomicrographs. Specimens of similarly prepared normal lymph nodes from C57BL/6 mice were used as controls.
CAMK2G Knockout by the CRISPR/Cas System sgRNA sequences targeting human CAMK2G were designed using the CRISPR on-line design tool (www.genome-engineering.org/ crispr). The designed sequence was cloned into the pX330 plasmid (Addgene). The 20 nt guiding sequences targeting exon1 and exon2 of human CAMK2G are shown below: 5'-TGCCAAGCTCCTCGAAGAGC-3' (target exon1 for clone A), 5'-GTGCTTTC TCTGTGGTCCGC-3' (target exon2 for clone B). The sgRNA-containing pX330 vector was co-transfected into 293T or H9 cells with the pMAX-GFP plasmid. After 48 hr, green fluorescent protein -positive (GFP + ) cells were single-cell sorted by fluorescence-activated cell sorting (FACS) into 96-well plates. Single clones were then expanded and screened by western blot analysis. Genomic DNA was purified from clones using the QIAamp DNA mini kit and underwent sequencing to verify the deletion.
C-Myc Ser62
Mutations Established by the CRISPR/Cas System sgRNAs for c-Myc Ser62 knock-in mutations were designed by Zhang laboratory CRISPR design tool ((http://crispr.mit.edu), annealed and ligated into pSpCas9n vecoter (pX461) digested by BbsI. The ssODN repair templates were designed with homologous genomic flanking sequence centered around the predicted CRISPR/Cas9 cleavage site. 500 ng of each pSpCas9n (sgRNA) plasmids with 1 ml of 10 mM ssODN were mixed for nucleofection into H9 cell lines with Cell Line Nucleofector Kit V (LONZA) followed its manual.
Two days after nucleofection, H9 cells were collected, washed by PBS and re-suspended with 1 ml of FACS medium. GFP + cells
were sorted into 96-well plates as single cell per well. The cells were incubated and expanded for 2-3 weeks, and all of the clones were further for genomic DNA extraction, PCR amplication of c-Myc sequence and Sanger sequencing. The correct S62A and S62D knock-in cell clones were selected for further experiments.
Colony Formation Assay
The colony formation assay was carried out using MethoCult TM H4230 methylcellulose medium (80 ml, StemCell Technologies), according to the manufacturer's instructions. Briefly, thaw the H4230 methylcellulose overnight at 4 C and add directly in the H4230 bottle with 20 ml Iscove's Modified Dulbecco's Medium (IMDM; StemCell Technologies, Cat #36150). Shake vigorously and leave overnight to settle, and then make aliquots. Cells were added to the mixed H4230 methylcellulose at 1000 cells/ml and dispensed to 6-well plates at 1 ml per well in triplicates. Colonies were counted after 14 days of culture at 37 C.
Cycloheximide (CHX) Chase Assay Cells were treated with 50 mM cycloheximide (CHX) and harvested at indicated time points. Protein was extracted from the cells and subjected to western blot analysis. Protein levels were measured with the densitometric intensity.
HaloTag (HT) Pulse-Chase Assay
The protein of interesting (POI) was cloned into HaloTag (HT) vector to establish HT-POI vector. Cells (1 3 10 6 cells in 6-well plates)
were transfected with 0.5 mg of HT-POI, and after cultured for 40 hr, cells were incubated with 5 mM HaloTag-tetramethylrhodamine (TMR) ligand (Promega) for 15 min to allow the pulse labeling of HT-POI, and washed twice with PBS. After the incubation for the indicated time, the cells were washed twice with PBS and suspended in lysis buffer. The whole cell extract was subjected to SDS-PAGE, and the TMR-labeled HT-POI was visualized with a fluoro-image analyzer FLA-3000G (FUJI FILM, Tokyo, Japan).
synthesis, end repair, adenylation of the 3' ends, and adapter ligation. The ligated material was amplified by PCR and then purified. The final library was 200-500 bp with a peak at approximately 280 bp. Libraries were loaded on an Illumina HiSeq 2500 for parallel sequencing.
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-Seq Data Analysis
The 51 bp-long single-ended sequence reads were mapped to the human genome (hg19) using TopHat; and the frequency of RefSeq genes detected was counted with customized R scripts. The raw counts were then normalized using the trimmed mean of M values (TMM) method implemented in the Bioconductor package edgeR. Low expression genes with rpkm values less than 5 in all samples were excluded from the differential expression analysis. Differentially expressed genes were identified by exact tests using edgeR, with an absolute fold-change R 1.5 as the cut off value. GO category enrichment analysis was performed with DAVID (Huang da et al., 2009), gene set enrichment analysis was performed in GSEA (Broad Institute) and upstream regulator analysis was generated through the use of QIAGEN's Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City).
Statistical Analysis
Student's t-test (two-sided) was applied, and changes were considered statistically significant for p < 0.05. For intercomparison of more than 2 groups, a one-way ANOVA followed by a post-hoc test was applied. To assess the association between c-Myc and CAMKIIg, Pearson correlation analysis was used. In the figures, changes are noted using *p < 0.05 and **p < 0.01. The data were normally distributed and variation within and between groups was not estimated. The sample size was not pre-selected and no inclusion/exclusion criteria were used. Survival in mouse experiments was represented with Kaplan-Meier curves, and significance was estimated with the log-rank test (Prism GraphPad). The data shown in the bar graphs are the mean and s.d. of at least three biological replicates. Statistical analysis was conducted using the Microsoft Excel or GraphPad Prism software packages.
DATA AND SOFTWARE AVAILABILITY
Data Resources RNA-seq data files have been deposited in the NCBI Gene Expression Omnibus under accession number GEO: GSE99364.
